How to Document Allergy and Immunology Patient Visits and Immunotherapy Treatment Plans

Allergy and immunology documentation sits at one of the more demanding intersections in outpatient medicine. A single patient may come in for a comprehensive evaluation, complete skin prick and intradermal testing across dozens of allergens, begin a multi-year subcutaneous immunotherapy protocol, require biologic management for severe asthma or atopic dermatitis, and eventually undergo a supervised food challenge. Every phase has distinct documentation requirements, and the records from the initial evaluation can remain clinically relevant for a decade.

This guide is written for allergists, immunologists, and advanced practice providers who want their notes to hold up for insurance reviewers, cross-covering clinicians, and the occasional medicolegal question about what happened in an anaphylaxis encounter.

Why Allergy Documentation Is More Complex Than It Looks

The challenge is that allergy practice blends several overlapping documentation contexts. You are writing clinical notes for each patient encounter, but you are also maintaining a longitudinal immunotherapy record that functions more like a medication administration log than a traditional progress note. Add in prior authorization letters for biologics, emergency action plans for patients at risk of anaphylaxis, and oral food challenge protocols that require specific pre- and post-challenge documentation, and the paperwork burden becomes real.

The other complexity is that allergy documentation is frequently reviewed by non-allergists. A primary care physician needs to understand what was tested and what was found. An emergency physician needs to know what allergens the patient has reacted to and what their emergency protocol is. An insurance reviewer needs enough detail to justify a biologic approval. Each of these readers has a different frame for your documentation.

Documenting the Initial Allergy Evaluation

The initial evaluation note is the anchor for everything that follows. A thorough intake captures not just the patient's current complaints but the full context that will drive diagnostic and treatment decisions for years.

Allergy History

Allergic history documentation should cover:

• Chief complaint framed in symptom terms, not diagnostic terms (not "allergies" but "nasal congestion, sneezing, and itchy eyes from March through June each year")
• Onset and duration of symptoms, with seasonal or perennial pattern noted
• Triggers the patient has identified, including foods, animals, medications, environmental exposures, and occupational exposures
• Prior allergy testing, including where it was done and what was found
• Prior treatment including antihistamines, nasal steroids, leukotriene modifiers, and any prior immunotherapy with dates, doses, and outcomes
• Atopic history: personal and family history of asthma, atopic dermatitis, allergic rhinitis, and food allergy
• Medication history with attention to beta-blockers, ACE inhibitors, and aspirin/NSAIDs, which affect anaphylaxis management and immunotherapy decisions
• Comorbidities including asthma control level, eosinophilic esophagitis, chronic urticaria, or mastocytosis

Fictional example: Maria, a 34-year-old elementary school teacher, presents with a six-year history of perennial nasal symptoms worse in spring and fall, and a two-year history of recurrent episodes of hives and throat tightness after eating at restaurants. Her primary care physician referred her after a reaction to a dish that may have contained tree nuts. She reports her older brother has asthma. She takes loratadine 10 mg PRN. No prior allergy testing. No beta-blockers. Dr. Elena Vargas's initial note captures this history in structured form before any testing begins, because the history drives the testing panel selection.

Review of Systems and Physical Exam

For allergy evaluations, the review of systems should at minimum address:

• Eyes (pruritus, conjunctival injection, chemosis, tearing)
• Nose (congestion, rhinorrhea, sneezing, loss of smell)
• Skin (urticaria, angioedema, eczematous changes, dermatographism)
• Respiratory (wheeze, dyspnea, cough, exercise limitation)
• Gastrointestinal (nausea, vomiting, cramping, diarrhea after eating)
• Cardiovascular (syncope, presyncope, palpitations during reactions)

The physical exam should document turbinate appearance, nasal polyps if present, skin findings with location and morphology, and a pulmonary exam including peak flow or spirometry results if asthma is on the differential.

Documenting Skin Prick Testing and Specific IgE Results

Allergy testing documentation needs to be specific enough that any subsequent allergist can reconstruct exactly what was tested and what the results showed.

Skin Prick Testing

Skin prick testing (SPT) documentation should include:

• Date and site of testing (typically volar forearm or upper back)
• Antihistamine and relevant medication hold period (document how many days since last antihistamine)
• Positive and negative controls with specific wheal and flare measurements
• Each allergen tested, by name and manufacturer/extract source if relevant, with wheal diameter in millimeters and flare diameter in millimeters
• Interpretation criteria used (for example, wheal ≥3 mm greater than negative control = positive)
• Results table format is far easier to read than a paragraph

For intradermal testing, document initial concentration used, any positive results at 1:1,000,000 or 1:100,000 dilution, and the progression if incremental testing was performed.

Fictional example note excerpt:

Skin prick testing performed on volar forearms. Positive control (histamine 10 mg/mL): wheal 8 mm / flare 22 mm. Negative control (saline): wheal 0 mm / flare 0 mm. Medications held: loratadine held 7 days prior to testing.

Selected results: Cashew: wheal 9 mm / flare 28 mm (POSITIVE). Walnut: wheal 7 mm / flare 21 mm (POSITIVE). Peanut: wheal 3 mm / flare 11 mm (borderline, to correlate with sIgE). Cat dander: wheal 11 mm / flare 30 mm (POSITIVE). Short ragweed: wheal 8 mm / flare 25 mm (POSITIVE). D. pteronyssinus: wheal 6 mm / flare 18 mm (POSITIVE).

Specific IgE Testing

Specific IgE (sIgE) results should be documented with the specific assay used (ImmunoCAP, Immulite), the allergen component when ordered (for example, Ara h 2 versus whole peanut extract), the numeric result in kU/L, and the class tier (Class 0 to Class 6). Document the clinical interpretation, not just the number. A cashew-specific IgE of 14.2 kU/L (Class 3) in a patient with a history of throat tightness after suspected cashew exposure carries different clinical weight than the same number in an asymptomatic patient.

When component-resolved diagnostics are ordered, name each component tested. For tree nut evaluation: Ana o 3 (cashew), Cor a 14 (hazelnut), Jug r 1 (walnut). Document the clinical significance of the component profile explicitly.

Allergen Immunotherapy: SCIT and SLIT Documentation

Immunotherapy documentation is a category of its own. The core records are distinct from visit notes and require their own structure.

SCIT Protocol Documentation

Subcutaneous immunotherapy (SCIT) requires several layers of documentation:

Treatment Set Documentation (typically completed before the first injection):

• Allergens included in the treatment vial set, with specific sources and concentrations
• Maintenance dose for each allergen component in the mix
• Escalation schedule (cluster, rush, or conventional build-up schedule with specific dose increments)
• Maximum allowable dose and criteria for dose adjustment
• Pre-medication protocol if used
• Emergency equipment available at the injection site

Per-Injection Records (for every administration):

• Date and time
• Lot number and expiration of each vial used
• Injection site (right or left arm, with location on arm noted)
• Dose administered (in milliliters) and vial concentration
• Pre-injection peak flow or symptom check if performed
• 20-30 minute observation period: start time and end time
• Any local reaction: describe size in millimeters, location, onset time
• Any systemic reaction: see anaphylaxis documentation below
• Clinician or staff member who administered and who observed

Dose Escalation Tracking:

A table format works far better than narrative for tracking build-up. For example:

When a dose adjustment is made (due to a large local reaction, a systemic reaction, or a missed injection period), document the reason for the adjustment and the new dose clearly.

Dose adjustment note example:

Patient presents for injection. Last injection was 6 weeks ago (missed appointment). Per protocol, dose reduced by one step from previously tolerated dose of 0.35 mL (Vial 3, 1:1,000) to 0.25 mL per protocol for injection gap greater than 4 weeks. Patient tolerated without local or systemic reaction. Observation period 30 minutes. No concerns.

SLIT Documentation

Sublingual immunotherapy (SLIT) documentation is different because administration occurs at home. Your records should capture:

• Prescription written, including allergen drops or tablet, starting dose, and escalation schedule
• Patient and/or caregiver education documented with specific topics covered (administration technique, emergency signs, when to skip a dose, how to manage local reactions)
• Return visit or phone contact notes at each escalation step documenting reported adherence and any reactions
• Maintenance dose reached and date

For FDA-approved SLIT tablets (Grastek for grass, Odactra for dust mite, Ragwitek for ragweed), document the specific product, that the first dose was administered in-office with 30-minute observation, and any pre-medication prescribed for the first dose.

Anaphylaxis Emergency Action Plans

Every patient identified as being at risk for anaphylaxis needs a documented emergency action plan (EAP), and the creation of that plan needs to be captured in your notes.

The EAP itself should contain:

• Patient name and date of birth
• Known trigger allergens
• Signs and symptoms to watch for, in plain patient-facing language
• Step-by-step instructions: when to use epinephrine, dose and device (for example, EpiPen 0.3 mg), when to call 911
• Secondary medications (antihistamine, oral corticosteroid) and their role
• Follow-up instructions post-reaction

In your clinical note, document:

• That the EAP was reviewed with the patient and/or caregiver
• Whether the patient can verbalize the steps back (teach-back documented)
• That an epinephrine auto-injector was prescribed (two-pack, with prescription in chart)
• Whether the patient carries the device at all times (self-report at each visit)
• Barriers to carrying or using epinephrine (cost, embarrassment, anxiety) with how those were addressed

Reaction documentation:

When a patient reports or presents with an anaphylactic reaction, document:

• Time of exposure and time of onset of symptoms
• Symptoms by organ system (cutaneous, respiratory, cardiovascular, gastrointestinal, neurological)
• Grading using the Ring and Messmer classification (Grade 1 through Grade 4) or equivalent
• Treatment given: epinephrine dose and route, time of administration, repeat doses if any
• Disposition (discharged home, observed in office, transferred to ED)
• Follow-up plan including tryptase draw timing if applicable (ideally 60-90 minutes after onset)

Documenting Biologic Medication Management

Biologic therapies for allergic disease have changed the treatment landscape for severe asthma, chronic urticaria, and atopic dermatitis. The documentation requirements around biologics are heavier than for most allergy medications because prior authorization is required, and the criteria are narrow.

Omalizumab (Xolair)

Omalizumab is indicated for moderate-to-severe persistent asthma with a demonstrated IgE-mediated mechanism, and for chronic idiopathic urticaria unresponsive to antihistamines. Your documentation must support the specific indication.

For asthma indication, document:

• Asthma severity classification (using NAEPP 2020 or GINA 2025 guidelines, with specific step)
• Documented IgE-mediated sensitization: positive skin test or sIgE to a perennial allergen
• Serum total IgE level (in IU/mL) and patient weight, since both determine dose
• Step therapy: adequate trial of inhaled corticosteroids (ICS) at appropriate doses with documented lack of control, and trial of add-on therapy such as LABA or leukotriene modifier
• ACQ (Asthma Control Questionnaire) or ACT (Asthma Control Test) scores at baseline and follow-up
• Exacerbation history (oral steroid courses, ED visits, hospitalizations in the prior 12 months)

For chronic urticaria indication:

• Duration of urticaria (must be at least 6 weeks for chronic classification)
• Trial of antihistamine at up to 4x standard dose with documented inadequate response
• UAS7 (Urticaria Activity Score 7) at baseline and follow-up

Dose calculation note example:

Omalizumab dose calculated based on total IgE 285 IU/mL and weight 72 kg. Per FDA prescribing table: 300 mg subcutaneous every 4 weeks. First injection administered in-office. Patient observed for 2 hours post-injection given high IgE level and first dose. No adverse reaction noted.

Dupilumab (Dupixent)

Dupilumab is used for moderate-to-severe atopic dermatitis, moderate-to-severe asthma with type 2 inflammation, and eosinophilic esophagitis. Documentation for prior authorization must include:

For atopic dermatitis:

• Disease extent and severity using a validated scale: IGA (Investigator's Global Assessment) score, EASI (Eczema Area and Severity Index), or SCORAD
• Prior treatment trial documentation: adequate and well-documented topical corticosteroid and/or topical calcineurin inhibitor trial, plus any systemic therapy (cyclosporine, methotrexate, or phototherapy) if indicated
• NRS itch score at baseline and follow-up

For asthma:

• Peripheral blood eosinophil count (supporting type 2 airway inflammation)
• FeNO (fractional exhaled nitric oxide) if measured, with the specific value in ppb
• Documented failure of ICS/LABA combination at high dose

Biologic monitoring documentation at each visit should include:

• Current dose and injection schedule
• Adverse effects: injection site reactions, eye symptoms for dupilumab users (conjunctivitis is a known adverse effect)
• Response measures: ACQ or ACT for asthma, itch NRS and EASI for atopic dermatitis
• Any dose delay or interruption with reason documented

Food Allergy Oral Challenge Documentation

Oral food challenges (OFC) are among the highest-risk procedures in outpatient allergy practice, and their documentation needs to reflect that.

Pre-Challenge Documentation

Before the challenge, your record should include:

• Clinical rationale for proceeding (why challenge now: negative testing trend, age-related tolerance development, equivocal history)
• Allergen-specific testing results at time of challenge decision (sIgE and SPT with dates)
• Informed consent for the OFC procedure: risks (anaphylaxis requiring epinephrine), benefits (confirmation of tolerance or allergy), alternatives (avoidance), and patient/parent questions and responses
• Exclusion criteria checked and cleared: no active asthma exacerbation, FEV1 or peak flow at baseline, no recent antihistamine use
• Emergency medications prepared and documented (epinephrine, diphenhydramine, oral corticosteroid, IV access if applicable)
• Challenge protocol selected: graded dose increments with specific doses and time intervals listed

During-Challenge Documentation

Document each dose administered with time, quantity of allergen, patient symptoms at each step, and clinician's assessment before proceeding. This is a contemporaneous real-time record, not a summary.

Fictional example excerpt:

OFC to cashew nut. Protocol: 6-step graded challenge. Baseline: patient symptom-free, peak flow 95% predicted, vital signs within normal limits.

08:32 – Dose 1: 0.1 mg cashew protein. Patient: no symptoms at 20 minutes. Proceed. 08:54 – Dose 2: 1 mg cashew protein. Patient: mild lip tingling, resolved within 5 minutes without treatment. No cutaneous or systemic signs. Dr. Vargas assessed, decision to proceed. 09:18 – Dose 3: 10 mg cashew protein. Patient reports throat tightness. Mild voice change noted. Stridor absent. Epinephrine 0.3 mg IM given to left thigh at 09:21. Symptoms resolved within 8 minutes. Challenge STOPPED. Positive challenge.

Post-Challenge Documentation

• Final diagnosis: positive (dose and symptoms that prompted stop) or negative (full dose tolerated)
• Treatment given during challenge if any (epinephrine dose, route, time; antihistamine; corticosteroid)
• Patient observation time post-challenge
• Disposition and discharge instructions
• Updated EAP provided
• Follow-up plan (next testing interval, risk counseling for positive challenge)

Asthma Comorbidity Tracking

Most allergists manage asthma as a primary or significant comorbid condition. Each encounter note for a patient with asthma should include a brief structured asthma assessment, not just buried in the narrative.

At every visit:

• Asthma Control Test (ACT) or ACQ score with the numeric result
• Controller medication adherence (and adherence barriers if relevant)
• Rescue inhaler use frequency in the past 4 weeks (in specific numbers, not "occasional" or "as needed")
• Spirometry or peak flow trend if available
• Exacerbations since last visit (oral corticosteroid courses, ED visits)
• Current GINA or NAEPP step level

Step changes should be documented with the clinical rationale. "Stepped up from Step 3 to Step 4 therapy. Patient has required 3 courses of oral prednisone in the past 6 months despite adherence to fluticasone/salmeterol 250/50 mcg twice daily. Added montelukast 10 mg nightly per Step 4 protocol. Discussed smoking cessation given patient's continued tobacco use."

Prior Authorization Documentation for Biologics

Prior authorization for biologics is one of the most time-consuming parts of allergy and immunology practice. Good documentation from the beginning saves hours of appeals work later.

The PA letter (or the chart documentation that supports the PA request) needs to include:

• Diagnosis with ICD-10 code (for example, J45.50 for severe persistent asthma uncomplicated)
• Disease severity documentation with objective measures (ACT score, FEV1 % predicted, exacerbation count)
• Step therapy documentation: names of prior medications tried, doses, duration of trial, and documented reason for failure (inadequate efficacy, adverse effect, or adherence despite trial)
• Specific biologic requested with FDA-approved indication and how the patient meets criteria
• Baseline objective measure that will be used to demonstrate response (ACT score, eosinophil count, EASI score)

When a PA is denied, document:

• The specific denial reason received from the payer
• Peer-to-peer review conducted (date, payer physician name, your arguments, outcome)
• Appeal letter sent (date, arguments, supporting literature cited)
• Whether the patient is using a manufacturer bridge program while appeal is pending

Fictional example: Dr. Vargas submits a PA for omalizumab for Maria, who now carries a diagnosis of moderate-to-severe allergic asthma. The PA letter references Maria's IgE of 285 IU/mL, positive sensitization to perennial allergens (dust mite SPT positive), ACT score of 14 (not well-controlled), three oral steroid courses in the past 12 months, and documented adherence to ICS/LABA at high dose. The insurer denies, requesting documentation of a leukotriene modifier trial. Dr. Vargas adds a note to the chart reflecting the peer-to-peer call, the argument made, and that montelukast was added in the interim as a step therapy bridge pending re-review.

Common Documentation Mistakes in Allergy Practice

Underdocumented testing interpretation. Listing wheal sizes without clinical interpretation leaves the next provider to guess what the numbers mean. Always add a brief interpretation sentence.

Missing pre-injection checks. Skipping documentation of the pre-injection symptom check or peak flow is an ACAAI best practice gap and a medicolegal exposure in the event of a post-injection reaction.

Vague local reaction records. "Small local reaction" is not specific enough. Document the wheal size in millimeters and its duration.

EAP not updated after dose change or new allergen identified. When you add a food allergen or change the patient's risk profile, update the EAP and document that it was updated.

Biologic monitoring notes without objective scores. "Patient doing well on dupilumab" without an EASI or ACT score is not a medical record; it is a reassurance statement. Document the numbers.

OFC protocol not documented before the challenge begins. If something goes wrong during a challenge, the absence of a pre-challenge protocol in the record is a significant liability gap.

Immunotherapy dose records kept separately from the problem-oriented chart without cross-reference. Ensure the allergy record, the injection log, and the visit notes are linked or cross-referenced so the full picture is accessible.

If you are using a structured documentation tool to build your templates, NotuDocs allows you to create specialty-specific templates for allergy evaluations, immunotherapy visit summaries, and biologic monitoring encounters, so each visit type has pre-structured fields for the specific data points that matter. The templates fill from your notes rather than generating content, which matters when documenting dose-specific records and reaction details where precision is clinical.

Allergy and Immunology Documentation Checklist

Initial Evaluation

• Chief complaint in symptom terms, not diagnostic shorthand
• Full atopic history including personal and family
• Prior testing and prior treatment documented with dates and outcomes
• Medication list with beta-blockers, ACE inhibitors, and NSAIDs specifically flagged
• Allergy-focused ROS covering eyes, nose, skin, lungs, and GI
• Physical exam with turbinate assessment, skin findings, and pulmonary exam

Skin Testing and sIgE

• Antihistamine hold period documented
• Positive and negative controls with measurements
• Each allergen tested by name with wheal and flare in millimeters
• Interpretation criteria stated
• sIgE results with assay used, numeric result in kU/L, class tier, and clinical interpretation
• Component-resolved results named by specific component (e.g., Ara h 2, Ana o 3)

Immunotherapy Records (SCIT)

• Treatment set documented with allergens, concentrations, and maintenance dose
• Escalation schedule on file
• Per-injection record: date, vial, dose, lot number, site, observation period, local reaction, systemic reaction, observer
• Dose adjustment notes with explicit reason and new dose
• Injection gap notation and protocol for dose reduction after gap

SLIT Documentation

• Prescription and starting dose documented
• First in-office dose with observation period documented
• Education content documented with teach-back
• Maintenance dose reached and date

Anaphylaxis and Emergency Action Plans

• EAP created, reviewed with patient, documented with teach-back
• Epinephrine auto-injector prescribed (two-pack) and documented
• Reaction documentation: onset, symptoms by organ system, Ring/Messmer grade, treatment with times, disposition
• EAP updated after any new allergen identification or dose change

Biologic Management

• Diagnosis with ICD-10 code documented
• Severity classification with objective score (ACT, ACQ, UAS7, EASI)
• Step therapy documented: prior agents, doses, duration, reason for failure
• Baseline measure recorded for response monitoring
• Dose calculation documented for omalizumab (IgE and weight)
• Per-visit biologic monitoring: dose, adverse effects, objective response score
• PA denials with peer-to-peer and appeal documentation

Oral Food Challenges

• Clinical rationale for OFC with testing data
• Informed consent with patient questions documented
• Pre-challenge clearance checks: asthma control, medication hold, FEV1 or peak flow
• Protocol documented with specific doses and time intervals before challenge begins
• Contemporaneous per-dose record during challenge
• Post-challenge documentation: final result, treatment given, observation time, updated EAP

Asthma Comorbidity

• ACT or ACQ numeric score at every visit
• Rescue inhaler use in specific numbers
• Current GINA or NAEPP step documented
• Step changes with clinical rationale

---

For related documentation guidance, see How to Document Urgent Care and Walk-In Clinic Patient Encounters and How to Document Behavioral Health Screenings in Primary Care.